## Healthcare Resource Utilization and **Costs of POAF Patients After** Cardiac Surgery: A Systematic Literature Review

Amy Wu,<sup>1,2</sup> Tae Jin Park,<sup>1</sup> Sara Higa,<sup>1</sup> Patrick Gillard<sup>1</sup>

<sup>1</sup>AbbVie, Irvine, California, USA ; <sup>2</sup>AMCP Foundation Intern

# OBJECTIVE

To characterize healthcare resource utilization and costs for patients with POAF following cardiac surgery and 30 days post-discharge

## CONCLUSIONS



Patients with POAF experience greater lengths of stay (1-4 days), readmission rates (2%), and higher total hospitalization costs (\$2,231-\$20,331).



POAF patients in the US typically experience longer lengths of stay and greater cost burden compared to Ex-US patients.



This review highlights the critical need for an effective prevention strategy for POAF.

#### For additional information or to obtain a PDF of this poster

Scan QR code or utilize the following link to download an electronic version of this presentation: [add link here for QR code] QR code expiration: March 19, 2022.



This study was sponsored by AbbVie Inc. (North Chicago, Illinois, USA). All authors met ICMJE authorship criteria. Neither honoraria nor payments were made for authorship.

Financial arrangements of the authors with companies whose products may be related to the present report are listed here as declared by the authors: T. Park is a fellow at the University of Washington and AbbVie Inc.; S. Higa is a former employee of AbbVie Inc.; P. Gillard is a fulltime employees of AbbVie Inc.; A. Wu participated in an internship at AbbVie Inc. through the AMCP Foundation Specialized Summer Internship in Health Outcomes that was funded by AbbVie Inc.

Poster presented at the Academy of Managed Care Pharmacy's Nexus, October 18 – October 21, 2021

- 2017;52(4):665-672.
- Shams Vahdati S. Samadikhah J. Hakim SH. et al. J Cardiovasc Thorac Res. 2012;4(1):17-20
- 2018:2018:3759238.





Greenberg JW, Lancaster TS, Schuessler RB, et al. Eur J Cardiothorac Surg.

Akintoye E, Sellke F, Marchioli R, et al. J Thorac Cardiovasc Surg. 2018;155(1):242-Frendl G, Sodickson AC, Chung MK, et al. J Thorac Cardiovasc Surg. 2014;148(3):e153-

Almassi GH, Wagner TH, Carr B, et al. Ann Thorac Surg. 2015;99(1):109-114.

LaPar DJ, Speir AM, Crosby IK, et al. Ann Thorac Surg. 2014;98(2):527-533.

. Farouk Musa A. Quan CZ. Xin LZ. et al. F1000Res. 2018:7:164. 8. Coletta MJ, Lis G, Clark P, et al. AACN Adv Crit Care. 2019;30(3):249-258. 9. Kosuma P, Wachirasrisirikul S, Jedsadayanmata A. Cardiol Res Pract.

10. Sezai A, Minami K, Nakai T, et al. J Thorac Cardiovasc Surg. 2011;141(6):1478-1487. 11. Hernández-Leiva É, Alvarado P, Dennis RJ. Braz J Cardiovasc Surg. 2019;34(2):179-186. Thank you to AbbVie, Inc.for funding the AMCP Foundation Specialized Summer Internship in Health Outcomes





#### INTRODUCTION

#### Background

- Post-operative atrial fibrillation (POAF) is one of the most common complications following open-chest cardiac surgery, occurring in  $\sim$ 35% of cases<sup>1</sup>
- POAF is associated with a longer hospital length of stay, as well as increased risk of stroke, acute kidney injury, and rehospitalization<sup>1,2</sup>
- Based on 2014 AATS guidelines, β-blockers are first-line therapy for POAF prevention<sup>3</sup>
- Second-line therapy includes amiodarone for prevention and treatment of intermediate to high-risk POAF patients<sup>3</sup>
- Currently, there is no drug with an FDA approved indication to prevent POAF

#### $\mathbf{e}$ RESULTS

#### **Study Characteristics**

A total of 8 studies spanned six count

#### Patient Characteristics

- Mean age of patients across these studies ranged widely from 55-71 years old • 8 studies included patients undergoing CABG; 5 studies excluded patients with prior AF

#### Length of Stay

### Table 1. Length of Stay

						Δ POAF v POAI	s No- =
HRU	Country	Author Year	N Total	No- POAF	POAF	<b>Δ Abs</b>	Δ Rel
Total	US	Coletta 2019 <sup>a</sup>	111	7 days	8 days	↑1 day	1.1x↑
		Coletta 2019 <sup>b</sup>	47	6 days	6 days	10	1x
	Japan	Sezai 2011	140	12 days	14.6 days	↑2.6 days*	1.2x↑
Hospital	Iran	Vahdati 2012	76	7.4 days	8.1 days	↑0.7 day	1.1x↑
LOS	Malaysia	Farouk Musa 2015	637	7.2 days	9 days	1.8 days*	1.3x
	Brazil	Hernandez 2017	44	9.5 days	13.1 days	13.6 days*	1.4x
	Thailand	Kosuma 2018	711	10 days	11 days	↑1 day*	1.1x↑
Post- Operative	US	LaPar 2014	49,264	5 days	7 days	↑2 days*	1.4x↑
		Almassi 2015	2,203	NR	NR	1) 13.9 days	N/A
LOS	Brazil	Hernandez 2017	44	5 days	9 days	↑4 days*	1.8x

#### **Readmission Rates**

#### Table 2. Hospital Readmission Rates

						Δ POA No-P	AF vs OAF
HRU	Country	Author Year	N Total	<b>No-POAF</b>	POAF	<b>Δ Abs</b>	Δ Rel
		LaPar 2014	49,264	7.5%	9.4%	1.9%*	1.3x
Hospital	05	Coletta 2019 <sup>a</sup>	111	11%	21%	10%	1.9x
Rates		Coletta 2019 <sup>b</sup>	47	15%	13%	↓2%	↓0.9x
	Malaysia	Farouk Musa 2015	637	2.9%	1.1%	↓1.8%	↓0.4x

## **METHODS**

#### Information Sources

 PubMed and EMBASE were searched for studies from 2011 to 2021; the search was limited to full-text publications, human subjects, and English language only

#### Eligibility Criteria

- Population of interest were adults who were 18 years or older who develop POAF after CABG and/or valvular surgery
- Outcomes included length of stay, hospital readmission rates, and costs

tries.	with	sample	sizes	ranging	from	44 -	49.264
uico,	VVILII	Sampic	51200	runging		TT	-0,20-

• POAF patients were associated with a greater total hospital, postoperative, and ICU LOS - 4/8 studies showed a significant increase ( $\uparrow 1-4$  days) in total hospital LOS • POAF patients in ex-US countries have a longer LOS compared to US POAF patients

• The absolute difference in hospital readmission rates ranged widely from 1.8%-10% – One study found a significant 2% increase in readmission rates for POAF patients

#### **Total Index Hospitalization Costs**



### **Post-Operative Costs**

- both groups



Graft; AF, Atrial Fibrillation;



• POAF patients were associated with greater total index hospitalization costs – 4/8 studies reported a significant increase ranging from \$2,753-\$20,331 in cost • There is a greater hospital cost burden in the US for POAF vs. Ex-US countries

 In every category of cost, POAF patients were associated with higher cost • Post-operative costs account for most of the differences in total hospital cost between



Note. All costs listed were unadjusted for confounders and were statistically significant. Absolute and relative differences were calculated by the investigator. All costs were adjusted to 2021 USD. <sup>a</sup> Pre-implementation data; <sup>b</sup> Implementation data; \*Statistically significant, \*\*Other costs may include supplies & devices, laboratory procedures, diagnostic imaging, physical therapy & rehabilitation and other unreported costs. Abbreviations: POAF, Post-Operative Atrial Fibrillation; AATS, American Association for Thoracic Surgery; ICU, Intensive Care Unit; LOS, Length of Stay; HRU, Healthcare Resource Utilization; Abs, Absolute; Rel, Relative; Hrs, Hours; NR, Not Referenced; CABG, Coronary Artery Bypass